LinkedIn
YouTube
DefiniGEN
Life Sciences • London • Early Stage
DefiniGEN is a spinout from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development.
Company
information
Total BGF investment
£2m
Investment date
November 2020
Head office
Cambridge
Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.
Dr Marcus Yeo , CEO
